ESSA Pharma Inc. (EPIX) Lowered to “Hold” at Bloom Burton

Bloom Burton cut shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) from a buy rating to a hold rating in a research note published on Tuesday morning.

Several other analysts also recently issued reports on the company. Zacks Investment Research upgraded ESSA Pharma from a strong sell rating to a hold rating in a research report on Tuesday, July 18th. ValuEngine downgraded ESSA Pharma from a sell rating to a strong sell rating in a research report on Wednesday, June 7th. Finally, Dawson James reiterated a buy rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. ESSA Pharma presently has an average rating of Hold and a consensus target price of $4.75.

Shares of ESSA Pharma (EPIX) opened at 0.3046 on Tuesday. ESSA Pharma has a 12 month low of $0.26 and a 12 month high of $2.80. The company’s 50 day moving average price is $0.31 and its 200-day moving average price is $1.97. The firm’s market capitalization is $8.86 million.

WARNING: This report was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.

Leave a Reply